APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pefloxacin Mesylate for Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pefloxacin Mesylate for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchPefloxacin Mesylate for Injection Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Pefloxacin Mesylate for Injection Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Pefloxacin Mesylate for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pefloxacin Mesylate for Injection Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Pefloxacin Mesylate for Injection Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Pefloxacin Mesylate for Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pefloxacin Mesylate for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pefloxacin Mesylate for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pefloxacin Mesylate for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pefloxacin Mesylate for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pefloxacin Mesylate for Injection include Chengdu Tiantaishan Pharmaceutical Co., Ltd., Furen Pharmaceutical Group Co., Ltd., Guangdong Xinghao Pharmaceutical Co., Ltd., Harbin Sanlian Pharmaceutical Co., Ltd., Harbin Songhe Pharmaceutical Co., Ltd., Haikou Qili Pharmaceutical Co., Ltd., Hainan General Kangli Pharmaceutical Co., Ltd., Hainan Zhuotai Pharmaceutical Co., Ltd. and Hubei Wushi Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pefloxacin Mesylate for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pefloxacin Mesylate for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pefloxacin Mesylate for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pefloxacin Mesylate for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Pefloxacin Mesylate for Injection Segment by Company

Chengdu Tiantaishan Pharmaceutical Co., Ltd.

Furen Pharmaceutical Group Co., Ltd.

Guangdong Xinghao Pharmaceutical Co., Ltd.

Harbin Sanlian Pharmaceutical Co., Ltd.

Harbin Songhe Pharmaceutical Co., Ltd.

Haikou Qili Pharmaceutical Co., Ltd.

Hainan General Kangli Pharmaceutical Co., Ltd.

Hainan Zhuotai Pharmaceutical Co., Ltd.

Hubei Wushi Pharmaceutical Co., Ltd.

Hunan Wuzhoutong Pharmaceutical Co., Ltd.

Hunan Yige Pharmaceutical Co., Ltd.

Jiangxi Gannan Haixin Pharmaceutical Co., Ltd.

Jincheng Haisi Pharmaceutical Co., Ltd.

Ruiyang Pharmaceutical Co., Ltd.

Shandong Phoenix Pharmaceutical Co., Ltd.

Sichuan Sanxingdui Pharmaceutical Co., Ltd.

Yantai Dongcheng North Pharmaceutical Co., Ltd.

Zhejiang Beide Pharmaceutical Co., Ltd.

Zhejiang Asia Pacific Pharmaceutical Co., Ltd.

Zhejiang Zuoli Pharmaceutical Co., Ltd.

Pefloxacin Mesylate for Injection Segment by Type

0.2g/Piece

0.4g/Piece

Pefloxacin Mesylate for Injection Segment by Application

Physical Pharmacies

Clinic

Other

Pefloxacin Mesylate for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pefloxacin Mesylate for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pefloxacin Mesylate for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pefloxacin Mesylate for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pefloxacin Mesylate for Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pefloxacin Mesylate for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pefloxacin Mesylate for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pefloxacin Mesylate for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pefloxacin Mesylate for Injection Industry Trends Table 2. Pefloxacin Mesylate for Injection Industry Drivers Table 3. Pefloxacin Mesylate for Injection Industry Opportunities and Challenges Table 4. Pefloxacin Mesylate for Injection Industry Restraints Table 5. Global Pefloxacin Mesylate for Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pefloxacin Mesylate for Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pefloxacin Mesylate for Injection Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Pefloxacin Mesylate for Injection Sales Market Share by Manufacturers Table 9. Global Pefloxacin Mesylate for Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pefloxacin Mesylate for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pefloxacin Mesylate for Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pefloxacin Mesylate for Injection Manufacturers, Product Type & Application Table 13. Global Pefloxacin Mesylate for Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pefloxacin Mesylate for Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 0.2g/Piece Table 17. Major Manufacturers of 0.4g/Piece Table 18. Global Pefloxacin Mesylate for Injection Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Pefloxacin Mesylate for Injection Sales by Type (2021-2026) & (K Units) Table 20. Global Pefloxacin Mesylate for Injection Sales by Type (2027-2032) & (K Units) Table 21. Global Pefloxacin Mesylate for Injection Sales Market Share by Type (2021-2026) Table 22. Global Pefloxacin Mesylate for Injection Sales Market Share by Type (2027-2032) Table 23. Global Pefloxacin Mesylate for Injection Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Pefloxacin Mesylate for Injection Revenue by Type (2021-2026) & (K Units) Table 25. Global Pefloxacin Mesylate for Injection Revenue by Type (2027-2032) & (K Units) Table 26. Global Pefloxacin Mesylate for Injection Revenue Market Share by Type (2021-2026) Table 27. Global Pefloxacin Mesylate for Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Physical Pharmacies Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Other Table 31. Global Pefloxacin Mesylate for Injection Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Pefloxacin Mesylate for Injection Sales by Application (2021-2026) & (K Units) Table 33. Global Pefloxacin Mesylate for Injection Sales by Application (2027-2032) & (K Units) Table 34. Global Pefloxacin Mesylate for Injection Sales Market Share by Application (2021-2026) Table 35. Global Pefloxacin Mesylate for Injection Sales Market Share by Application (2027-2032) Table 36. Global Pefloxacin Mesylate for Injection Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Pefloxacin Mesylate for Injection Revenue by Application (2021-2026) & (K Units) Table 38. Global Pefloxacin Mesylate for Injection Revenue by Application (2027-2032) & (K Units) Table 39. Global Pefloxacin Mesylate for Injection Revenue Market Share by Application (2021-2026) Table 40. Global Pefloxacin Mesylate for Injection Revenue Market Share by Application (2027-2032) Table 41. Global Pefloxacin Mesylate for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Pefloxacin Mesylate for Injection Sales by Region (2021-2026) & (K Units) Table 43. Global Pefloxacin Mesylate for Injection Sales Market Share by Region (2021-2026) Table 44. Global Pefloxacin Mesylate for Injection Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Pefloxacin Mesylate for Injection Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Pefloxacin Mesylate for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Pefloxacin Mesylate for Injection Sales by Country (2021-2026) & (K Units) Table 48. North America Pefloxacin Mesylate for Injection Sales by Country (2027-2032) & (K Units) Table 49. Europe Pefloxacin Mesylate for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Pefloxacin Mesylate for Injection Sales by Country (2021-2026) & (K Units) Table 51. Europe Pefloxacin Mesylate for Injection Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Pefloxacin Mesylate for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Pefloxacin Mesylate for Injection Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Pefloxacin Mesylate for Injection Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Pefloxacin Mesylate for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Pefloxacin Mesylate for Injection Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Pefloxacin Mesylate for Injection Sales by Country (2027-2032) & (K Units) Table 58. Global Pefloxacin Mesylate for Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Pefloxacin Mesylate for Injection Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Pefloxacin Mesylate for Injection Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Pefloxacin Mesylate for Injection Revenue Market Share by Region (2021-2026) Table 62. Global Pefloxacin Mesylate for Injection Revenue Market Share by Region (2027-2032) Table 63. Chengdu Tiantaishan Pharmaceutical Co., Ltd. Company Information Table 64. Chengdu Tiantaishan Pharmaceutical Co., Ltd. Business Overview Table 65. Chengdu Tiantaishan Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Chengdu Tiantaishan Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 67. Chengdu Tiantaishan Pharmaceutical Co., Ltd. Recent Development Table 68. Furen Pharmaceutical Group Co., Ltd. Company Information Table 69. Furen Pharmaceutical Group Co., Ltd. Business Overview Table 70. Furen Pharmaceutical Group Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Furen Pharmaceutical Group Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 72. Furen Pharmaceutical Group Co., Ltd. Recent Development Table 73. Guangdong Xinghao Pharmaceutical Co., Ltd. Company Information Table 74. Guangdong Xinghao Pharmaceutical Co., Ltd. Business Overview Table 75. Guangdong Xinghao Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Guangdong Xinghao Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 77. Guangdong Xinghao Pharmaceutical Co., Ltd. Recent Development Table 78. Harbin Sanlian Pharmaceutical Co., Ltd. Company Information Table 79. Harbin Sanlian Pharmaceutical Co., Ltd. Business Overview Table 80. Harbin Sanlian Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Harbin Sanlian Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 82. Harbin Sanlian Pharmaceutical Co., Ltd. Recent Development Table 83. Harbin Songhe Pharmaceutical Co., Ltd. Company Information Table 84. Harbin Songhe Pharmaceutical Co., Ltd. Business Overview Table 85. Harbin Songhe Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Harbin Songhe Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 87. Harbin Songhe Pharmaceutical Co., Ltd. Recent Development Table 88. Haikou Qili Pharmaceutical Co., Ltd. Company Information Table 89. Haikou Qili Pharmaceutical Co., Ltd. Business Overview Table 90. Haikou Qili Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Haikou Qili Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 92. Haikou Qili Pharmaceutical Co., Ltd. Recent Development Table 93. Hainan General Kangli Pharmaceutical Co., Ltd. Company Information Table 94. Hainan General Kangli Pharmaceutical Co., Ltd. Business Overview Table 95. Hainan General Kangli Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Hainan General Kangli Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 97. Hainan General Kangli Pharmaceutical Co., Ltd. Recent Development Table 98. Hainan Zhuotai Pharmaceutical Co., Ltd. Company Information Table 99. Hainan Zhuotai Pharmaceutical Co., Ltd. Business Overview Table 100. Hainan Zhuotai Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hainan Zhuotai Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 102. Hainan Zhuotai Pharmaceutical Co., Ltd. Recent Development Table 103. Hubei Wushi Pharmaceutical Co., Ltd. Company Information Table 104. Hubei Wushi Pharmaceutical Co., Ltd. Business Overview Table 105. Hubei Wushi Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Hubei Wushi Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 107. Hubei Wushi Pharmaceutical Co., Ltd. Recent Development Table 108. Hunan Wuzhoutong Pharmaceutical Co., Ltd. Company Information Table 109. Hunan Wuzhoutong Pharmaceutical Co., Ltd. Business Overview Table 110. Hunan Wuzhoutong Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Hunan Wuzhoutong Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 112. Hunan Wuzhoutong Pharmaceutical Co., Ltd. Recent Development Table 113. Hunan Yige Pharmaceutical Co., Ltd. Company Information Table 114. Hunan Yige Pharmaceutical Co., Ltd. Business Overview Table 115. Hunan Yige Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Hunan Yige Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 117. Hunan Yige Pharmaceutical Co., Ltd. Recent Development Table 118. Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Company Information Table 119. Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Business Overview Table 120. Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 122. Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Recent Development Table 123. Jincheng Haisi Pharmaceutical Co., Ltd. Company Information Table 124. Jincheng Haisi Pharmaceutical Co., Ltd. Business Overview Table 125. Jincheng Haisi Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Jincheng Haisi Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 127. Jincheng Haisi Pharmaceutical Co., Ltd. Recent Development Table 128. Ruiyang Pharmaceutical Co., Ltd. Company Information Table 129. Ruiyang Pharmaceutical Co., Ltd. Business Overview Table 130. Ruiyang Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Ruiyang Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 132. Ruiyang Pharmaceutical Co., Ltd. Recent Development Table 133. Shandong Phoenix Pharmaceutical Co., Ltd. Company Information Table 134. Shandong Phoenix Pharmaceutical Co., Ltd. Business Overview Table 135. Shandong Phoenix Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Shandong Phoenix Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 137. Shandong Phoenix Pharmaceutical Co., Ltd. Recent Development Table 138. Sichuan Sanxingdui Pharmaceutical Co., Ltd. Company Information Table 139. Sichuan Sanxingdui Pharmaceutical Co., Ltd. Business Overview Table 140. Sichuan Sanxingdui Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Sichuan Sanxingdui Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 142. Sichuan Sanxingdui Pharmaceutical Co., Ltd. Recent Development Table 143. Yantai Dongcheng North Pharmaceutical Co., Ltd. Company Information Table 144. Yantai Dongcheng North Pharmaceutical Co., Ltd. Business Overview Table 145. Yantai Dongcheng North Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Yantai Dongcheng North Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 147. Yantai Dongcheng North Pharmaceutical Co., Ltd. Recent Development Table 148. Zhejiang Beide Pharmaceutical Co., Ltd. Company Information Table 149. Zhejiang Beide Pharmaceutical Co., Ltd. Business Overview Table 150. Zhejiang Beide Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Zhejiang Beide Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 152. Zhejiang Beide Pharmaceutical Co., Ltd. Recent Development Table 153. Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Company Information Table 154. Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Business Overview Table 155. Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 157. Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Recent Development Table 158. Zhejiang Zuoli Pharmaceutical Co., Ltd. Company Information Table 159. Zhejiang Zuoli Pharmaceutical Co., Ltd. Business Overview Table 160. Zhejiang Zuoli Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Zhejiang Zuoli Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio Table 162. Zhejiang Zuoli Pharmaceutical Co., Ltd. Recent Development Table 163. Key Raw Materials Table 164. Raw Materials Key Suppliers Table 165. Pefloxacin Mesylate for Injection Distributors List Table 166. Pefloxacin Mesylate for Injection Customers List Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Pefloxacin Mesylate for Injection Product Image Figure 2. Global Pefloxacin Mesylate for Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pefloxacin Mesylate for Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Pefloxacin Mesylate for Injection Sales (2021-2032) & (K Units) Figure 5. Global Pefloxacin Mesylate for Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pefloxacin Mesylate for Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 0.2g/Piece Image Figure 9. 0.4g/Piece Image Figure 10. Global Pefloxacin Mesylate for Injection Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Pefloxacin Mesylate for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Pefloxacin Mesylate for Injection Sales Market Share by Type (2021-2032) Figure 13. Global Pefloxacin Mesylate for Injection Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Pefloxacin Mesylate for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Pefloxacin Mesylate for Injection Revenue Market Share by Type (2021-2032) Figure 16. Physical Pharmacies Image Figure 17. Clinic Image Figure 18. Other Image Figure 19. Global Pefloxacin Mesylate for Injection Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Pefloxacin Mesylate for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Pefloxacin Mesylate for Injection Sales Market Share by Application (2021-2032) Figure 22. Global Pefloxacin Mesylate for Injection Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Pefloxacin Mesylate for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Pefloxacin Mesylate for Injection Revenue Market Share by Application (2021-2032) Figure 25. North America Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Pefloxacin Mesylate for Injection Sales Market Share by Country (2021-2032) Figure 27. U.S. Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Pefloxacin Mesylate for Injection Sales Market Share by Country (2021-2032) Figure 32. Germany Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Pefloxacin Mesylate for Injection Sales Market Share by Country (2021-2032) Figure 39. China Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Pefloxacin Mesylate for Injection Sales Market Share by Country (2021-2032) Figure 47. Brazil Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Pefloxacin Mesylate for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Pefloxacin Mesylate for Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Pefloxacin Mesylate for Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Pefloxacin Mesylate for Injection Revenue (2021-2032) & (US$ Million) Figure 58. North America Pefloxacin Mesylate for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Pefloxacin Mesylate for Injection Revenue (2021-2032) & (US$ Million) Figure 60. Europe Pefloxacin Mesylate for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Pefloxacin Mesylate for Injection Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Pefloxacin Mesylate for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Pefloxacin Mesylate for Injection Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Pefloxacin Mesylate for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Pefloxacin Mesylate for Injection Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Pefloxacin Mesylate for Injection Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 0.2g/Piece
  • 0.4g/Piece
Applications
  • Physical Pharmacies
  • Clinic
  • Other
Companies covered
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Furen Pharmaceutical Group Co., Ltd.
  • Guangdong Xinghao Pharmaceutical Co., Ltd.
  • Harbin Sanlian Pharmaceutical Co., Ltd.
  • Harbin Songhe Pharmaceutical Co., Ltd.
  • Haikou Qili Pharmaceutical Co., Ltd.
  • Hainan General Kangli Pharmaceutical Co., Ltd.
  • Hainan Zhuotai Pharmaceutical Co., Ltd.
  • Hubei Wushi Pharmaceutical Co., Ltd.
  • Hunan Wuzhoutong Pharmaceutical Co., Ltd.
  • Hunan Yige Pharmaceutical Co., Ltd.
  • Jiangxi Gannan Haixin Pharmaceutical Co., Ltd.
  • Jincheng Haisi Pharmaceutical Co., Ltd.
  • Ruiyang Pharmaceutical Co., Ltd.
  • Shandong Phoenix Pharmaceutical Co., Ltd.
  • Sichuan Sanxingdui Pharmaceutical Co., Ltd.
  • Yantai Dongcheng North Pharmaceutical Co., Ltd.
  • Zhejiang Beide Pharmaceutical Co., Ltd.
  • Zhejiang Asia Pacific Pharmaceutical Co., Ltd.
  • Zhejiang Zuoli Pharmaceutical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pefloxacin Mesylate for Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pefloxacin Mesylate for Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pefloxacin Mesylate for Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pefloxacin Mesylate for Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pefloxacin Mesylate for Injection Market Dynamics
  1. 2.1 Pefloxacin Mesylate for Injection Industry Trends
  2. 2.2 Pefloxacin Mesylate for Injection Industry Drivers
  3. 2.3 Pefloxacin Mesylate for Injection Industry Opportunities and Challenges
  4. 2.4 Pefloxacin Mesylate for Injection Industry Restraints
3 Pefloxacin Mesylate for Injection Market by Manufacturers
  1. 3.1 Global Pefloxacin Mesylate for Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pefloxacin Mesylate for Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pefloxacin Mesylate for Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pefloxacin Mesylate for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pefloxacin Mesylate for Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pefloxacin Mesylate for Injection Manufacturers, Product Type & Application
  7. 3.7 Global Pefloxacin Mesylate for Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pefloxacin Mesylate for Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pefloxacin Mesylate for Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pefloxacin Mesylate for Injection Tier 1, Tier 2, and Tier 3
4 Pefloxacin Mesylate for Injection Market by Type
  1. 4.1 Pefloxacin Mesylate for Injection Type Introduction
  2. 4.1.1 0.2g/Piece
  3. 4.1.2 0.4g/Piece
  4. 4.2 Global Pefloxacin Mesylate for Injection Sales by Type
  5. 4.2.1 Global Pefloxacin Mesylate for Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pefloxacin Mesylate for Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Pefloxacin Mesylate for Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Pefloxacin Mesylate for Injection Revenue by Type
  9. 4.3.1 Global Pefloxacin Mesylate for Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pefloxacin Mesylate for Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Pefloxacin Mesylate for Injection Revenue Market Share by Type (2021-2032)
5 Pefloxacin Mesylate for Injection Market by Application
  1. 5.1 Pefloxacin Mesylate for Injection Application Introduction
  2. 5.1.1 Physical Pharmacies
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Pefloxacin Mesylate for Injection Sales by Application
  6. 5.2.1 Global Pefloxacin Mesylate for Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pefloxacin Mesylate for Injection Sales by Application (2021-2032)
  8. 5.2.3 Global Pefloxacin Mesylate for Injection Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pefloxacin Mesylate for Injection Revenue by Application
  10. 5.3.1 Global Pefloxacin Mesylate for Injection Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pefloxacin Mesylate for Injection Revenue by Application (2021-2032)
  12. 5.3.3 Global Pefloxacin Mesylate for Injection Revenue Market Share by Application (2021-2032)
6 Global Pefloxacin Mesylate for Injection Sales by Region
  1. 6.1 Global Pefloxacin Mesylate for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pefloxacin Mesylate for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Pefloxacin Mesylate for Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Pefloxacin Mesylate for Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pefloxacin Mesylate for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pefloxacin Mesylate for Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pefloxacin Mesylate for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pefloxacin Mesylate for Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pefloxacin Mesylate for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pefloxacin Mesylate for Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pefloxacin Mesylate for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pefloxacin Mesylate for Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pefloxacin Mesylate for Injection Revenue by Region
  1. 7.1 Global Pefloxacin Mesylate for Injection Revenue by Region
  2. 7.1.1 Global Pefloxacin Mesylate for Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pefloxacin Mesylate for Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Pefloxacin Mesylate for Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Pefloxacin Mesylate for Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pefloxacin Mesylate for Injection Revenue (2021-2032)
  8. 7.2.2 North America Pefloxacin Mesylate for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pefloxacin Mesylate for Injection Revenue (2021-2032)
  11. 7.3.2 Europe Pefloxacin Mesylate for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pefloxacin Mesylate for Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pefloxacin Mesylate for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pefloxacin Mesylate for Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pefloxacin Mesylate for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  2. 8.1.1 Chengdu Tiantaishan Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Chengdu Tiantaishan Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Chengdu Tiantaishan Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chengdu Tiantaishan Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  6. 8.1.5 Chengdu Tiantaishan Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Furen Pharmaceutical Group Co., Ltd.
  8. 8.2.1 Furen Pharmaceutical Group Co., Ltd. Company Information
  9. 8.2.2 Furen Pharmaceutical Group Co., Ltd. Business Overview
  10. 8.2.3 Furen Pharmaceutical Group Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Furen Pharmaceutical Group Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  12. 8.2.5 Furen Pharmaceutical Group Co., Ltd. Recent Developments
  13. 8.3 Guangdong Xinghao Pharmaceutical Co., Ltd.
  14. 8.3.1 Guangdong Xinghao Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Guangdong Xinghao Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Guangdong Xinghao Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Guangdong Xinghao Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  18. 8.3.5 Guangdong Xinghao Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Harbin Sanlian Pharmaceutical Co., Ltd.
  20. 8.4.1 Harbin Sanlian Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Harbin Sanlian Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Harbin Sanlian Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Harbin Sanlian Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  24. 8.4.5 Harbin Sanlian Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Harbin Songhe Pharmaceutical Co., Ltd.
  26. 8.5.1 Harbin Songhe Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Harbin Songhe Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Harbin Songhe Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Harbin Songhe Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  30. 8.5.5 Harbin Songhe Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Haikou Qili Pharmaceutical Co., Ltd.
  32. 8.6.1 Haikou Qili Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Haikou Qili Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Haikou Qili Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Haikou Qili Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  36. 8.6.5 Haikou Qili Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Hainan General Kangli Pharmaceutical Co., Ltd.
  38. 8.7.1 Hainan General Kangli Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Hainan General Kangli Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Hainan General Kangli Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hainan General Kangli Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  42. 8.7.5 Hainan General Kangli Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 Hainan Zhuotai Pharmaceutical Co., Ltd.
  44. 8.8.1 Hainan Zhuotai Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Hainan Zhuotai Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Hainan Zhuotai Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hainan Zhuotai Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  48. 8.8.5 Hainan Zhuotai Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Hubei Wushi Pharmaceutical Co., Ltd.
  50. 8.9.1 Hubei Wushi Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Hubei Wushi Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Hubei Wushi Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hubei Wushi Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  54. 8.9.5 Hubei Wushi Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Hunan Wuzhoutong Pharmaceutical Co., Ltd.
  56. 8.10.1 Hunan Wuzhoutong Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Hunan Wuzhoutong Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Hunan Wuzhoutong Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hunan Wuzhoutong Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  60. 8.10.5 Hunan Wuzhoutong Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Hunan Yige Pharmaceutical Co., Ltd.
  62. 8.11.1 Hunan Yige Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 Hunan Yige Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 Hunan Yige Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hunan Yige Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  66. 8.11.5 Hunan Yige Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Jiangxi Gannan Haixin Pharmaceutical Co., Ltd.
  68. 8.12.1 Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  72. 8.12.5 Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Jincheng Haisi Pharmaceutical Co., Ltd.
  74. 8.13.1 Jincheng Haisi Pharmaceutical Co., Ltd. Company Information
  75. 8.13.2 Jincheng Haisi Pharmaceutical Co., Ltd. Business Overview
  76. 8.13.3 Jincheng Haisi Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Jincheng Haisi Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  78. 8.13.5 Jincheng Haisi Pharmaceutical Co., Ltd. Recent Developments
  79. 8.14 Ruiyang Pharmaceutical Co., Ltd.
  80. 8.14.1 Ruiyang Pharmaceutical Co., Ltd. Company Information
  81. 8.14.2 Ruiyang Pharmaceutical Co., Ltd. Business Overview
  82. 8.14.3 Ruiyang Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Ruiyang Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  84. 8.14.5 Ruiyang Pharmaceutical Co., Ltd. Recent Developments
  85. 8.15 Shandong Phoenix Pharmaceutical Co., Ltd.
  86. 8.15.1 Shandong Phoenix Pharmaceutical Co., Ltd. Company Information
  87. 8.15.2 Shandong Phoenix Pharmaceutical Co., Ltd. Business Overview
  88. 8.15.3 Shandong Phoenix Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Shandong Phoenix Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  90. 8.15.5 Shandong Phoenix Pharmaceutical Co., Ltd. Recent Developments
  91. 8.16 Sichuan Sanxingdui Pharmaceutical Co., Ltd.
  92. 8.16.1 Sichuan Sanxingdui Pharmaceutical Co., Ltd. Company Information
  93. 8.16.2 Sichuan Sanxingdui Pharmaceutical Co., Ltd. Business Overview
  94. 8.16.3 Sichuan Sanxingdui Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sichuan Sanxingdui Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  96. 8.16.5 Sichuan Sanxingdui Pharmaceutical Co., Ltd. Recent Developments
  97. 8.17 Yantai Dongcheng North Pharmaceutical Co., Ltd.
  98. 8.17.1 Yantai Dongcheng North Pharmaceutical Co., Ltd. Company Information
  99. 8.17.2 Yantai Dongcheng North Pharmaceutical Co., Ltd. Business Overview
  100. 8.17.3 Yantai Dongcheng North Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Yantai Dongcheng North Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  102. 8.17.5 Yantai Dongcheng North Pharmaceutical Co., Ltd. Recent Developments
  103. 8.18 Zhejiang Beide Pharmaceutical Co., Ltd.
  104. 8.18.1 Zhejiang Beide Pharmaceutical Co., Ltd. Company Information
  105. 8.18.2 Zhejiang Beide Pharmaceutical Co., Ltd. Business Overview
  106. 8.18.3 Zhejiang Beide Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Zhejiang Beide Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  108. 8.18.5 Zhejiang Beide Pharmaceutical Co., Ltd. Recent Developments
  109. 8.19 Zhejiang Asia Pacific Pharmaceutical Co., Ltd.
  110. 8.19.1 Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Company Information
  111. 8.19.2 Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Business Overview
  112. 8.19.3 Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  114. 8.19.5 Zhejiang Asia Pacific Pharmaceutical Co., Ltd. Recent Developments
  115. 8.20 Zhejiang Zuoli Pharmaceutical Co., Ltd.
  116. 8.20.1 Zhejiang Zuoli Pharmaceutical Co., Ltd. Company Information
  117. 8.20.2 Zhejiang Zuoli Pharmaceutical Co., Ltd. Business Overview
  118. 8.20.3 Zhejiang Zuoli Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Zhejiang Zuoli Pharmaceutical Co., Ltd. Pefloxacin Mesylate for Injection Product Portfolio
  120. 8.20.5 Zhejiang Zuoli Pharmaceutical Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pefloxacin Mesylate for Injection Value Chain Analysis
  2. 9.1.1 Pefloxacin Mesylate for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pefloxacin Mesylate for Injection Production Mode & Process
  6. 9.2 Pefloxacin Mesylate for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pefloxacin Mesylate for Injection Distributors
  9. 9.2.3 Pefloxacin Mesylate for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst